Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.56 |
| ▸ | BCR | P11274 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347641 | 0.92 | ABL1 (0.62) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5351819 | 0.89 | CYP1A2 (0.62) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5344061 | 0.88 | ABL1 (0.56) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5343983 | 0.87 | ABL1 (0.55) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5355726 | 0.87 | CYP1A2 (0.60) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5357407 | 0.86 | ABL1 (0.56) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5344234 | 0.86 | ABL1 (0.56) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5355746 | 0.85 | ABL1 (0.53) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5344003 | 0.83 | ABL1 (0.53) | ABL1BCRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5347144 | 0.83 | CYP1A2 (0.54) | ABL1BCRCYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007507531-A | — | — | 2007-03-29 | — | — | JP | claimed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | claimed |
| EP-1670771-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-06-21 | — | — | EP | claimed |
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC (BM) | 2005-08-04 | — | — | US | claimed |
| WO-2005033086-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-14 | — | — | WO | claimed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | disclosed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | disclosed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | disclosed |
| EP-1670771-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-06-21 | — | — | EP | disclosed |
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC (BM) | 2005-08-04 | — | — | US | disclosed |
| WO-2005033086-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | ERBB2, ERBB3, ERBB4 | ABL1 72/4885BCR 58/4885CYP1A2 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.